Next quarter’s earnings estimate for LSTA is -$0.51 with a range of -$0.51 to -$0.51. The previous quarter’s EPS was -$0.49. LSTA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year LSTA has Performed in-line its overall industry.
Next quarter’s earnings estimate for LSTA is -$0.51 with a range of -$0.51 to -$0.51. The previous quarter’s EPS was -$0.49. LSTA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year LSTA has Performed in-line its overall industry.
LSTA Sales Forecast
Next quarter’s sales forecast for LSTA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. LSTA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year LSTA has Performed in-line its overall industry.
Next quarter’s sales forecast for LSTA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. LSTA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year LSTA has Performed in-line its overall industry.
Lisata Therapeutics: Promising Pipeline and Strong Financials Support Buy RatingValuation and risks to price target achievement. We reiterate our Buy rating and price target of $15. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug's potential commercial profile. Our valuation is based on the LSTA1 opportunity for pancreatic cancer (75% contribution) and colorectal cancer (25% contribution). Factors that could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway.
Lisata Therapeutics: Promising Pipeline and Strong Financials Support Buy RatingValuation and risks to price target achievement. We reiterate our Buy rating and price target of $15. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug's potential commercial profile. Our valuation is based on the LSTA1 opportunity for pancreatic cancer (75% contribution) and colorectal cancer (25% contribution). Factors that could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway.
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +3.59% per trade.
trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -9.97% per trade.
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -21.37% per trade.
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -27.51% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
LSTA Analyst Recommendation Trends
Rating
Jan 25
Feb 25
Jun 25
Jul 25
Aug 25
Strong Buy
2
1
1
3
4
Buy
0
0
0
0
0
Hold
14
10
5
1
0
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
11
6
4
4
In the current month, LSTA has received 4Buy Ratings, 0Hold Ratings, and 0Sell Ratings. LSTA average Analyst price target in the past 3 months is ―.
Each month's total comprises the sum of three months' worth of ratings.
LSTA Stock Forecast FAQ
What is LSTA’s average 12-month price target, according to analysts?
Currently, no data Available
What is LSTA’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for LSTA, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is LSTA a Buy, Sell or Hold?
Lisata Therapeutics has a consensus rating of Moderate Buy which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
What is Lisata Therapeutics’s price target?
Currently, no data Available
What do analysts say about Lisata Therapeutics?
Lisata Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 0 Wall Streets Analysts.
How can I buy shares of LSTA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.